SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody, Rabbit MAb
RRID Number: AB_2827973
COVID-19 Nucleocapsid Research.
COVID-19 Nucleocapsid Research.
Cat: 40143-R019
SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody, Rabbit MAb の製品情報
製品名
SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody, Rabbit MAb
検証済のアプリケーション
WB,ELISA
アプリケーションの説明
IHC, FCM, IF, IP et al. applications haven't been validated.
(Antibody's applications haven't been validated with corresponding virus positive samples. Optimal concentrations/dilutions should be determined by the end user.)
特異性
2019-nCoV Coronavirus Nucleocapsid
Has cross-reactivity in ELISA and WB with
SARS-CoV Nucleocapsid Protein (Cat# 40143-V08B)
No cross-reactivity in ELISA with
MERS-CoV Nucleoprotein protein (40068-V08B)
HCoV-229E Nucleoprotein protein (40640-V07E)
HCoV-NL63 Nucleoprotein protein (40641-V07E)
HCoV-HKU1(isolate N5) Nucleoprotein protein (40642-V07E)
HCoV-OC43 Nucleoprotein (40643-V07E)
Has cross-reactivity in ELISA and WB with
SARS-CoV Nucleocapsid Protein (Cat# 40143-V08B)
No cross-reactivity in ELISA with
MERS-CoV Nucleoprotein protein (40068-V08B)
HCoV-229E Nucleoprotein protein (40640-V07E)
HCoV-NL63 Nucleoprotein protein (40641-V07E)
HCoV-HKU1(isolate N5) Nucleoprotein protein (40642-V07E)
HCoV-OC43 Nucleoprotein (40643-V07E)
調製
This product is a recombinant monoclonal antibody expressed from HEK293 cells.
ソース
Monoclonal Rabbit IgG Clone #019
精製
Protein A
緩衝液
0.2 μm filtered solution in PBS
標識物
Unconjugated
状態
Liquid
配送方法
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
保存条件
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody, Rabbit MAb 検証済のアプリケーション
| アプリケーション | 推奨希釈率/用量 |
|---|---|
| WB | 1:1000-1:5000 |
| ELISA | 1:5000-1:10000 |
Please Note: Optimal concentrations/dilutions should be determined by the end user.
SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody, Rabbit MAb の画像
Anti-2019-nCoV NP rabbit monoclonal antibody at 1:1000 dilution.
Sample: 2019-nCoV NP Protein (Cat# 40588-V08B)
Lane A: 30ng
Lane B: 10ng
Lane C: 5ng
Lane D: 2ng
Lane E: 1ng
Lane F: 0.5ng
Secondary
Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution.
Developed using the ECL technique.
Performed under reducing conditions.
SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody, Rabbit MAb: 別名
Anti-coronavirus NP Antibody; Anti-coronavirus Nucleocapsid Antibody; Anti-coronavirus Nucleoprotein Antibody; Anti-cov np Antibody; Anti-ncov NP Antibody; Anti-NCP-CoV Nucleocapsid Antibody; Anti-novel coronavirus NP Antibody; Anti-novel coronavirus Nucleocapsid Antibody; Anti-novel coronavirus Nucleoprotein Antibody; Anti-np Antibody; Anti-nucleocapsid Antibody; Anti-Nucleoprotein Antibody
Coronavirus Nucleocapsid 背景情報
Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.
参考文献
- 1.Van Boheemen S, et al. (2012), MBio. 3(6):e00473-12.
- Bisht H. et al., 2004, Proc Natl Acad Sci. 101 (17): 6641-6.
- Li W. et al., 2005, Science. 309 (5742): 1864-8.
-
Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19)AuthorLarsen, CP;Bourne, TD;Wilson, JD;Saqqa, O;Sharshir, MA;Year2020JournalKidney Int RepApplicationIHC
-
Proteomics of SARS-CoV-2-infected host cells reveals therapy targetsAuthorBojkova, D;Klann, K;Koch, B;Widera, M;Krause, D;Ciesek, S;Cinatl, J;Münch, C;Year2020JournalNatureApplicationViraM infection assay
-
The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph NodesAuthorFeng, Z;Diao, B;Wang, R;Wang, G;Wang, C;Tan, Y;Year2020JournalmedRxiv
-
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2AuthorWang, H;Zhang, Y;Huang, B;Deng, W;Quan, Y;Wang, W;Xu, W;Zhao, Y;Li, N;Zhang, J;Liang, H;Bao, L;Xu, Y;Ding, L;Zhou, W;Gao, H;Liu, J;Niu, P;Zhao, L;Zhen, W;Fu, H;Yu, S;Zhang, Z;Xu, G;Li, C;Lou, Z;Xu, M;Qin, C;Wu, G;Gao, G;Tan, W;Yang, X;Year2020JournalCellApplicationWB
-
Sofosbuvir protects human brain organoids against SARS-CoV-2AuthorMesci, P;Macia, A;Saleh, A;Martin-Sancho, L;Yin, X;Snethlage, C;Avansini, S;Chanda, S;Muotri, A;Year2020JournalbioRxivApplicationIF
-
上海 2 株严重急性呼吸综合征冠状病毒 2 的分离与鉴定Author彭浩然, ;李成忠, ;唐海琳, ;薛建亚, ;陈志辉, ;梁雪松, ;朱咏梅, ;夏炳辉, ;朱勇喆, ;吴俊杰, ;赵兰娟, ;任浩, ;江亮亮, ;何燕华, ;戚中田, ;赵平, ;Year2020Journal第二军医大学学报
-
SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patientsAuthorKlimstra, W;Tilston-Lunel, N;Nambulli, S;Boslett, J;McMillen, C;Gilliland, T;Dunn, M;Sun, C;Wheeler, S;Wells, A;Hartman, A;McElroy, A;Reed, D;Rennick, L;Duprex, W;Year2020JournalbioRxivApplicationImmunoplaque assay
-
Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2AuthorTakeda, Y;Murata, T;Jamsransuren, D;Suganuma, K;Kazami, Y;Batkhuu, J;Badral, D;Ogawa, H;Year2020JournalViruses
Recombinant Antibody Production Service
High-throughput Recombinant Antibody Production
